| abstract |
Non-therapeutic method for the in-vitro modulation of the TRPM8 cold menthol receptor, in which the receptor is brought into contact with at least one modulator, which is selected from compounds of the following structure type 3: structure type 3: ** (See formula)** where R31, R32, R33, R34 and R35 are the same or different and are selected from H; halogen; straight-chain or branched C1-C6 alkyl groups optionally bearing 1, 2, 3 or 4 identical or different substituents selected from NH2, OH, SH, halogen or straight-chain or branched C1-C6 alkoxy groups; straight-chain or branched C1-C6 alkoxy groups optionally bearing 1, 2, 3 or 4 identical or different substituents, selected from NH2, OH, SH, halogen or C1-C6 alkoxy groups; aryl, arylalkyl and heteroaryl mononuclear or multinucleated groups, optionally bearing 1, 2, 3 or 4 identical or different substituents, selected from NH2, OH, SH, halogen, C1-C6 alkyl groups of straight chain or branched and C1-C6 straight chain or branched alkyloxy groups; in which the heteroaryl groups have 1, 2, 3 or 4 ring heteroatoms, which are the same or different and are selected from O, N and S; or two adjacent radicals R31, R32, R33, R34 and R35 together with the carbon atoms to which they are attached form a 4-, 5-, 6- or 7-membered, mono- or polyunsaturated heterocyclic ring, optionally bearing 1 , 2, 3, 4 or 5 the same or different substituents, selected from C1-C6 straight chain or branched alkyl groups, and having 1, 2 or 3 ring heteroatoms, which are the same or different and selected from O , N and S; R36 and R37 are the same or different and are selected from: straight-chain or branched C1-C6 alkyl groups bearing optionally 1, 2, 3 or 4 identical or different substituents, selected from NH2, OH, SH, halogen or straight chain or branched C1-C6 alkoxy groups; aryl, arylalkyl, aryloxy, heteroaryl and heteroaryloxy, single or multinucleated, optionally bearing 1, 2, 3 or 4 identical or different substituents, selected from NH2, OH, SH, halogen, alkyl groups C1-C6 straight chain or branched and C1-C6 straight chain or branched alkoxy groups; in which the heteroaryl groups have 1, 2, 3 or 4 ring heteroatoms, which are the same or different and are selected from O, N and S; and C3-C7 cycloalkyl groups, optionally carrying 1, 2, 3 or 4 identical or different substituents, selected from NH2, OH, SH, halogen, straight-chain or branched C1-C6 alkyl groups, or alkoxy groups C1-C6 straight chain or branched; in which the cycloalkyl group is optionally attached via a C1-C4 alkylene group; and in which, if appropriate, 1, 2 or 3 ring carbon atoms may be substituted by the same or different heteroatoms, selected from O, N and S; X is selected from C1-C4 alkylene groups; C2-C4 alkenylene groups, as well as -Z-C1-C4 or -C1-C4-Z alkylene groups or -Z-C2-C4 or -C2-C4-Z alkenylene groups, wherein Z represents O, S or NH; o represents a chemical single bond; as well as salts of these compounds, in particular acid addition salts with inorganic or in particular organic, monovalent or in particular polyvalent carboxylic acids; and optionally in stereoisomerically pure form or as a mixture of stereoisomers, in which the condition is fulfilled that the compound of formula (III) is not 1-(2-aminoethyl)-1-(1,3-benzothiazole hydrochloride 1-(2-aminoethyl)-1-(1,3-benzothiazol-2-yl)-3-[(1R)- -2-yl)-3-[(1S)-1-phenylethyl]urea, 1-phenylethyl]urea, **(See formula)** and **(See formula)** |